Thus, while it is evident that JAK1, JAK2, and B2M mutations can contribute to immune resistance in multiple types of cancer, the loss of IFNγ signaling gene expression may be the predominant source of ICB resistance in colorectal cancer. The gene discussed is IFNG; the disease is cancer.